AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 22 min read$TVTX

Travere Therapeutics Non-GAAP EPS of -$0.31 misses by $0.73, revenue of $224.5M beats by $29.21M (TVTX:NASDAQ)

Travere Therapeutics reported Q3 Non-GAAP EPS of -$0.31, missing estimates by $0.73. Revenue was $224.5M, up 36.1% Y/Y and beating estimates by $29.21M. R&D expenses were $63.2M for the quarter and $168.1M for the nine months. (TVTX)

Original reporting
seekingalpha.com
Published Nov 2, 2026, 9:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TVTX
Bearish
high confidence
Mentioned
$TVTX
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$TVTXBearishMed
01

Why it matters

The earnings miss may trigger short‑term downside, but revenue growth could support longer‑term upside if pipeline advances.

02

Market read

First‑report earnings for TVTX; material EPS miss likely moves the stock in after‑hours trading.

03

What to watch

Potential pipeline milestones or upcoming regulatory decisions not covered in the brief.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Travere Therapeutics released its Q3 2026 non‑GAAP earnings, highlighting an EPS miss and revenue beat.

Company-level read

Ticker impact

$TVTXBearishHigh confidence
Context

Q3 non‑GAAP EPS of -$0.31 missed expectations by $0.73 and revenue of $224.5M beat estimates by $29.21M.

Expected impact

downward pressure as investors price in the EPS miss

Evidence & confidence

The EPS shortfall is material for a biotech; revenue beat may not offset the miss, prompting a sell‑off.

Market effects

Sector

Biotech earnings miss may weigh on peer valuations in the rare‑disease space.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Revenue beat could signal underlying growth, offering a buying opportunity on dip.

Key entities

  • company
    Travere Therapeutics

    Biopharmaceutical company focused on rare kidney diseases.

Read at source← All news

StoryTravere Therapeutics reports Q3 2026 loss and revenue beat amid high R&D spend

Also covered by

2 outlets

Related articles

NOV 3
$TVTXMedAI 8/10

Why is Travere Therapeutics stock sliding today?

Travere Therapeutics (TVTX) shares fell 4.3% in pre-market trading after reporting Q3 2026 results. The company missed earnings estimates due to a $113.1M R&D expense, despite revenue beating expectations. Leerink Partners cut its price target to $67 from $78. CEO Eric Dube sold shares in mid-October. FILSPARI sales grew 120% YoY, but Q4 inventory normalization may impact revenue.

investing.com6 min
NOV 3
$TVTXMed

Travere (TVTX) Q3 2026 Earnings Call Transcript

Travere (TVTX) reported Q3 2026 earnings, highlighting strong performance of its drug Filspari, with quarterly net product sales surpassing $200 million. The company expects to achieve or exceed $3 billion in annual Filspari sales by 2033, driven by growing patient demand and a strengthened patent portfolio. Travere also discussed progress in its pipeline, including Pegtibatinase for classical HCU and Civorebrutinib for immune-mediated kidney diseases.

finance.yahoo.com3 min
NOV 3
$TVTXMed

Travere: Q3 Earnings Snapshot

Travere Therapeutics (TVTX) reported a Q3 loss of $52.3M, or 55 cents per share, missing analyst estimates of a 25 cents loss per share. Revenue was $224.6M, exceeding forecasts of $192.5M. The drug developer's earnings fell short of expectations.

finance.yahoo.com1 min
NOV 3
$TVTXMed

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Travere Therapeutics (TVTX) reported Q3 earnings, with FILSPARI sales at $8M. The company expects Q4 sales to be reduced by a similar amount due to inventory adjustments. TVTX sees opportunities for FILSPARI in the evolving IgAN market and highlighted positive clinical data. Expenses totaled $168.7M, including $113.1M in R&D. CEO Eric Dube will step down in December. TVTX reiterated its $3B sales target for FILSPARI by 2033.

finance.yahoo.com3 min